Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)

• Main Authors: Stav Brown (Author), Audree B. Tadros (Author), Giacomo Montagna (Author), Tajah Bell (Author), Fionnuala Crowley (Author), Emily J. Gallagher (Author), Joseph H. Dayan (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2024-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

PurposePatients undergoing axillary lymph node dissection (ALND) for breast cancer face a high risk of lymphedema, further increased by high body mass index (BMI) and insulin resistance. GLP-1 receptor agonists (GLP-1RAs) have the potential to reduce these risk factors, but their role in lymphedema...